[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342941-105":59,"doc-detail-342941-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","overcoming-barriers-in-glioblastomaadvances-in-drug-delivery-strategies","Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies","","Rapid evolution in cancer therapy has improved outcomes for many patients, yet major malignancies still show limited therapeutic gains. Glioblastoma, the most common malignant primary brain tumor, remains clinically challenging despite laboratory sensitivity to numerous chemotherapeutics. The blood–brain barrier (BBB) contributes to high failure rates by restricting drug access to the brain. This review explains BBB function in healthy and glioblastoma contexts and summarizes strategies developed to pass or open the BBB to reach brain tumors and improve patient prospects.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/overcoming-barriers-in-glioblastomaadvances-in-drug-delivery-strategies/342941/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/overcoming-barriers-in-glioblastomaadvances-in-drug-delivery-strategies/342941.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is glioblastoma treatment still difficult despite chemotherapy sensitivity in the lab?","Question",{"text":112,"@type":113},"Glioblastoma has poor clinical prospects even when laboratory tests show sensitivity to chemotherapeutics. A major contributor is restricted drug access caused by the blood–brain barrier (BBB).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What role does the blood–brain barrier play in therapeutic failure?",{"text":117,"@type":113},"The BBB regulates exchange between blood and brain and prevents neurotoxic agents and pathogens from entering. In glioblastoma, it limits access of many therapeutic agents, contributing to high failure rates and reduced brain concentrations of drugs like TMZ.",{"name":119,"@type":110,"acceptedAnswer":120},"What approaches does the review cover to improve drug delivery to brain tumors?",{"text":121,"@type":113},"The review discusses strategies to manipulate or open the BBB as well as local approaches designed to circumvent the BBB. It aims to enable access to brain tumors and improve patient outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342941,1790143478,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","cells  \nReview  \nOvercoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies  \nEsther ter Linden 1, Erik R. Abels 1, Thomas S. van Solinge 2, Jacques Neefjes 1 and Marike L. D. Broekman 1,2,3, *  \nCitation: ter Linden, E.; Abels, E.R.; van Solinge, T.S.; Neefjes, J.; Broekman, M.L.D. Overcoming Barriers in Glioblastoma—Advancesin Drug Delivery Strategies. Cells 2024, 13, 998. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells13120998](10.3390/cells13120998)  \nAcademic Editor: Swapan K. Ray  \nReceived: 8 May 2024  \nRevised: 3 June 2024  \nAccepted: 5 June 2024  \nPublished: 7 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; [e.ter_linden@lumc.nl](e.ter_linden@lumc.nl) (E.t.L.); [e.r.abels@lumc.nl](e.r.abels@lumc.nl) (E.R.A.)  \n2 Department of Neurosurgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands; [t.s.van_solinge@lumc.nl](t.s.van_solinge@lumc.nl)  \n3 Department of Neurosurgery, Haaglanden Medical Center, 2512 VA The Hague, The Netherlands  \n* [Correspondence: m.l.d.broekman@lumc.nl](Correspondence: m.l.d.broekman@lumc.nl)  \nAbstract: The world of cancer treatment is evolving rapidly and has improved the prospects of many cancer patients. Yet, there are still many cancers where treatment prospects have not (or hardly) improved. Glioblastoma is the most common malignant primary brain tumor, and eventhough it is sensitive to many chemotherapeutics when tested under laboratory conditions, its clinical prospects are still very poor. The blood–brain barrier (BBB) is considered at least partly responsible for the high failure rate of many promising treatment strategies. We describe the workings of the BBB during healthy conditions and within the glioblastoma environment. How the BBB acts as a barrier for therapeutic options is described as well as various approaches developed and tested for passing or opening the BBB, with the ultimate aim to allow access to brain tumors and improve patient perspectives.  \nKeywords: blood–brain barrier; glioblastoma; drug delivery; focused ultrasound; chemotherapy; nanoparticle  \n1. Introduction  \nCancer treatment has been improving fast, and new tumor treatment strategies like targeted therapies and immunotherapy have enlarged in the treatment field for many different cancer types. Unfortunately, not all cancer patients have benefited from these new strategies, and the treatment of primary brain tumors still highly relies on surgical resection, with dissatisfactory results [1,2] .  \nGliomas are diffuse-growing primary brain tumors that arise from glial progenitor cells. Glioblastoma (GBM) is the most common malignant primary brain tumor and accounts for 14.2% of all CNS tumors and 50.9% of all malignant brain tumors [3] . The standard of care for GBM consists of maximal safe neurosurgical resection, followed by postoperative radiotherapy with concomitant and adjuvant treatment with temozolomide (TMZ), a DNA alkylating cancer drug. Unfortunately, the effect of this treatment regimen is limited, and relapse is common, resulting in a median overall survival of only 15 months [4,5] .  \nThe only substantial change to this regimen has been the addition of Tumor Treating Fields (TTFs) . Since 2014, this non-invasive technique of alternating electrical fields inducing anti-cancer effects via a multitude of biological processes is approved as an addition to the standard-of-care therapy [6] . The first clinical results imply a substantial improvement in overall survival of several months, which is now being ","cbCaieNePFg59JpO","https://ap.wps.com/l/cbCaieNePFg59JpO","pdf",2142260,"English","# Abstract\n# Introduction\n## Glioblastoma background and current standard of care\n## BBB limitations and drug delivery need\n# Blood–Brain Barrier","[{\"question\":\"Why is glioblastoma treatment still difficult despite chemotherapy sensitivity in the lab?\",\"answer\":\"Glioblastoma has poor clinical prospects even when laboratory tests show sensitivity to chemotherapeutics. A major contributor is restricted drug access caused by the blood–brain barrier (BBB).\"},{\"question\":\"What role does the blood–brain barrier play in therapeutic failure?\",\"answer\":\"The BBB regulates exchange between blood and brain and prevents neurotoxic agents and pathogens from entering. In glioblastoma, it limits access of many therapeutic agents, contributing to high failure rates and reduced brain concentrations of drugs like TMZ.\"},{\"question\":\"What approaches does the review cover to improve drug delivery to brain tumors?\",\"answer\":\"The review discusses strategies to manipulate or open the BBB as well as local approaches designed to circumvent the BBB. It aims to enable access to brain tumors and improve patient outcomes.\"}]","Overcoming Barriers in Glioblastoma—Advances in Drug Delivery Strategies | PDF",1790048970,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24f74d35705a4ecddb54f373f01938d4.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d85a74653389fd1e9e1d77858a70c7d.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4fb24e218a37f3463345c6f1291c2dc.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3a67b09ef6c8260bfb1465d5283cfd4.webp",980,1385]